Among the top five factors secreted by CAFs in lung cancer, FST surprisingly emerged as a critical player in rescuing cancer cells from EGFR-TKI-induced toxicity, and thus represents a potential target to combat drug resistance in NSCLC (Figure 3A). This evidence concerns the gene EGFR and non-small cell lung carcinoma.